This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

28 Sep 2011

Lonza & Mesoblast Ink Manufacturing Pact for Stem Cell Products

Lonza has entered into a strategic alliance with Australia-based Mesoblast for the production of Mesoblast's adult stem cell therapies.

Switzerland-based pharma Lonza has formed a partnership with Australia-based regenerative medicine company Mesoblast to produce its off-the-shelf (allogeneic) adult stem cell products.


According to their agreement, Lonza will supply Mesoblast’s clinical and long-term commercial MPC product needs globally.


Mesoblast can instruct Lonza to build a dedicated manufacturing plant exclusively for its products in exchange for buying "agreed quantities" of these products from the facility.


Mesoblast can exercise its right to buy out this manufacturing facility at a pre-agreed purchase price two years after the facility receives regulatory approval.

Related News